Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1Barrett Esophagus 1

Interventions

fludarabine 6Cyclophosphamide 5fludarabine phosphate 4Whole-Body Irradiation 4itacitinib 3angiotensin I (1-7) 3pembrolizumab 2Tacrolimus 2Olanzapine 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2INCB039110 2CTLA-4 Antigen 2Busulfan 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2AP 1903 reagent 2tazemetostat 1tafasitamab 1ruxolitinib 1pomalidomide 1ofatumumab 1merphos 1lopinavir-ritonavir drug combination 1ivosidenib 1ibrutinib 1fedratinib 1enasidenib 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hematologic Neoplasms × Endoscopy × Clear all
NCT05660421 2026-04-27

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡